new england journal of medicine semaglutide The In an interim analysis of
Description
The companys revenue has skyrocketed since it began selling compounded GLP-1s, from $271.9 million in 2021 to $1.5 billion in 2024
Its taken my 74 years to learn what portion control can really look like. (P5, female, obesity)
doi: 10.1111/apt.18138 98 VillumsenMScheldeABJimenez-SolemEJessTAllinKH
Recently, anecdotal accounts and raw event incidence reports prompted FDA to review a potential association between GLP-1 RAs and suicidal ideation
Tirzepatide for managing overweight and obesity prescribing, reviewing and stopping (TA1026)
When we trivialise the root cause of obesity as little more than a lack of willpower, we overlook crucial factors that place those living with the disease at a striking biological disadvantage
